Entrectinib for treating relapsed or refractory locally advanced or metastatic solid tumours with NTRK1/2/3 gene fusions in children and adults

Entrectinib is in clinical development for the treatment of children and adolescents with relapsed (recurrent) or refractory (treatment resistant) locally advanced or metastatic solid or primary tumours harbouring neurotropic tropomyosin receptor kinase (NTRK) 1/2/3. Solid tumours are defined as abnormal masses of tissue that usually do not contain cysts or liquid areas and may be benign or malignant. Some solid tumours may be caused by specific genetic changes, for example, mutation in the NTRK genes, which can affect signalling inside the cell which drives cell growth and cause an uncontrolled increase of cancer cells. These gene mutations are rare, hence the need for effective therapies that can target gene alterations shared by multiple tumour types regardless of site of origin.